Market Cap 16.66B
Revenue (ttm) 982.02M
Net Income (ttm) -416.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.39%
Debt to Equity Ratio -8.30
Volume 3,345,500
Avg Vol 2,288,810
Day's Range N/A - N/A
Shares Out 132.60M
Stochastic %K 54%
Beta 1.61
Analysts Strong Sell
Price Target $138.05

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling t...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 698 8887
Fax: 888 974 4258
Address:
3100 Hanover Street, Palo Alto, United States
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 2:56 PM
$GH Some 128s to Guard the Port ⚔️
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 12:40 PM
$GH Initiated at Buy GS PT 165
0 · Reply
TheBullishTrade
TheBullishTrade Jun. 4 at 11:01 PM
$GH $NBIS $MX $AMPG $TRT My eyes are open to all sectors, but my passion has always been technology—including healthcare technology. There are countless opportunities out there, and I’m here to share what I find with all of you. There are simply too many ticker symbols to track, which is why I spend 4–5 hours every day researching, not to pump stocks, but to bring awareness to companies that may be flying under the radar. Just look at the gains some of these names have made since I first posted about them. As I always say, I don’t claim to be perfect with every call. Some work out, some don’t. Many of these stocks don’t move immediately—it can take days, weeks, or even longer for the thesis to play out. In fact, several of the stocks I’ve highlighted actually pulled back right after I posted them. My goal is to educate traders and introduce companies you may not be familiar with but that have a compelling investment thesis behind them. All I ask is that you take the time to understand what the company actually does and evaluate whether the bullish thesis makes sense. If you disagree, that’s completely fine. I’m simply here to share research and ideas. What you do with that information is entirely up to you.
2 · Reply
OffHisGame88
OffHisGame88 Jun. 4 at 8:15 PM
$GH adding more here. I see $200 before long
0 · Reply
PhotonicDigger
PhotonicDigger Jun. 4 at 8:03 PM
$GH is gearing up for a bull flag breakout! Backed by the American Cancer Society adding Shield to its guidelines and explosive Q1 revenue growth, momentum is heavy. Do you think this breakout holds or are you waiting for a pullback? Let me know!
0 · Reply
WAJeff
WAJeff Jun. 4 at 7:02 PM
$GH $134.28 52 week high
0 · Reply
Gator5326
Gator5326 Jun. 4 at 6:47 PM
$GH just getting started. $GH $200 by December
0 · Reply
OG_Monkey_Banana_Genius
OG_Monkey_Banana_Genius Jun. 4 at 3:17 PM
$NTRA $GH 😮 . LONG
1 · Reply
JFDI
JFDI Jun. 4 at 3:00 PM
0 · Reply
Albino_Trader123
Albino_Trader123 Jun. 4 at 2:16 PM
$GH Outside of Semis GH looks ready.
0 · Reply
Latest News on GH
Guardant Health initiated with a Buy at Goldman Sachs

2026-06-05T08:35:20.000Z - 1 day ago

Guardant Health initiated with a Buy at Goldman Sachs


Guardant Health assumed with an Outperform at Wolfe Research

2026-06-01T20:54:41.000Z - 5 days ago

Guardant Health assumed with an Outperform at Wolfe Research


Guardant Health management to meet with Craig-Hallum

2026-05-27T16:54:18.000Z - 10 days ago

Guardant Health management to meet with Craig-Hallum


Guardant Health price target raised to $160 from $155 at BTIG

2026-05-27T16:52:39.000Z - 10 days ago

Guardant Health price target raised to $160 from $155 at BTIG


Blood test added to US colorectal cancer screening options

May 27, 2026, 7:03 AM EDT - 10 days ago

Blood test added to US colorectal cancer screening options


Guardant Health management to meet with Craig-Hallum

2026-05-26T20:46:44.000Z - 11 days ago

Guardant Health management to meet with Craig-Hallum


Guardant Health price target raised to $155 from $145 at BTIG

2026-05-26T11:40:35.000Z - 11 days ago

Guardant Health price target raised to $155 from $145 at BTIG


Guardant Health Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Guardant Health Earnings Call Transcript: Q1 2026


Guardant Health Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Guardant Health Earnings release: Q1 2026


Guardant Health Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Guardant Health Slides: Q1 2026


Guardant Health Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Guardant Health Quarterly report: Q1 2026


Guardant Health receives FDA approval for Guardant360 CDx

2026-05-04T12:34:42.000Z - 4 weeks ago

Guardant Health receives FDA approval for Guardant360 CDx

ARVN PFE


Guardant Health to Participate in Upcoming Investor Conferences

Apr 29, 2026, 4:05 PM EDT - 5 weeks ago

Guardant Health to Participate in Upcoming Investor Conferences


Guardant Health Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Guardant Health Proxy statement: Proxy filing


Guardant Health Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Guardant Health Proxy statement: Proxy filing


Guardant Health Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Guardant Health Earnings Call Transcript: Q4 2025


Guardant Health Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Guardant Health Annual report: Q4 2025


Guardant Health Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Guardant Health Earnings release: Q4 2025


Guardant Health Slides: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Guardant Health Slides: Q4 2025


Guardant Health Transcript: 7th Annual Healthcare Symposium

Nov 14, 2025, 8:50 AM EST - 7 months ago

Guardant Health Transcript: 7th Annual Healthcare Symposium


Guardant Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Guardant Health Earnings Call Transcript: Q3 2025


Guardant Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Guardant Health Quarterly report: Q3 2025


Guardant Health Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Guardant Health Earnings release: Q3 2025


Guardant Health Slides: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Guardant Health Slides: Q3 2025


Guardant Health Transcript: Investor Day 2025

Sep 24, 2025, 9:00 AM EDT - 9 months ago

Guardant Health Transcript: Investor Day 2025


Guardant Health Slides: FY 2025

Sep 24, 2025, 9:00 AM EDT - 9 months ago

Guardant Health Slides: FY 2025


Alex M. Azar II Joins Guardant Health Board of Directors

Sep 15, 2025, 4:07 PM EDT - 9 months ago

Alex M. Azar II Joins Guardant Health Board of Directors


NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 2:56 PM
$GH Some 128s to Guard the Port ⚔️
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 12:40 PM
$GH Initiated at Buy GS PT 165
0 · Reply
TheBullishTrade
TheBullishTrade Jun. 4 at 11:01 PM
$GH $NBIS $MX $AMPG $TRT My eyes are open to all sectors, but my passion has always been technology—including healthcare technology. There are countless opportunities out there, and I’m here to share what I find with all of you. There are simply too many ticker symbols to track, which is why I spend 4–5 hours every day researching, not to pump stocks, but to bring awareness to companies that may be flying under the radar. Just look at the gains some of these names have made since I first posted about them. As I always say, I don’t claim to be perfect with every call. Some work out, some don’t. Many of these stocks don’t move immediately—it can take days, weeks, or even longer for the thesis to play out. In fact, several of the stocks I’ve highlighted actually pulled back right after I posted them. My goal is to educate traders and introduce companies you may not be familiar with but that have a compelling investment thesis behind them. All I ask is that you take the time to understand what the company actually does and evaluate whether the bullish thesis makes sense. If you disagree, that’s completely fine. I’m simply here to share research and ideas. What you do with that information is entirely up to you.
2 · Reply
OffHisGame88
OffHisGame88 Jun. 4 at 8:15 PM
$GH adding more here. I see $200 before long
0 · Reply
PhotonicDigger
PhotonicDigger Jun. 4 at 8:03 PM
$GH is gearing up for a bull flag breakout! Backed by the American Cancer Society adding Shield to its guidelines and explosive Q1 revenue growth, momentum is heavy. Do you think this breakout holds or are you waiting for a pullback? Let me know!
0 · Reply
WAJeff
WAJeff Jun. 4 at 7:02 PM
$GH $134.28 52 week high
0 · Reply
Gator5326
Gator5326 Jun. 4 at 6:47 PM
$GH just getting started. $GH $200 by December
0 · Reply
OG_Monkey_Banana_Genius
OG_Monkey_Banana_Genius Jun. 4 at 3:17 PM
$NTRA $GH 😮 . LONG
1 · Reply
JFDI
JFDI Jun. 4 at 3:00 PM
0 · Reply
Albino_Trader123
Albino_Trader123 Jun. 4 at 2:16 PM
$GH Outside of Semis GH looks ready.
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 4 at 1:40 PM
$GH 128 is your friend
0 · Reply
Gator5326
Gator5326 Jun. 2 at 3:51 PM
$GH Analyst $136.94 Based on analysts offering 12 month price targets for GH in the last 3 months. The average price target is $136.94 with a high estimate of $160 and a low estimate of $120.
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 2 at 12:59 PM
Tuesday’s biggest analyst calls: Wedbush upgrades TripAdvisor to outperform from neutral Daiwa reiterates Nvidia as outperform Goldman Sachs downgrades Intuit to sell from neutral Evercore ISI upgrades Guardant Health to outperform from in line Piper Sandler initiates Take-Two Interactive as overweight $TRIP $NVDA $INTU $GH $TTWO
1 · Reply
G101SPM
G101SPM Jun. 2 at 11:54 AM
$GH $131.10 +1.96 CORE LONG TERM HOLDING WITH NET COST OF $16.49 https://stocktwits.com/G101SPM/message/645421812 BRIEF: Guardant Health (GH) upgraded to Outperform from In Line at Evercore ISI, tgt $160
0 · Reply
Estimize
Estimize Jun. 1 at 11:03 AM
Wall St is expecting -0.75 EPS for $GH Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gh?chart=historical&metric_name=eps&utm_conte
0 · Reply
Snozz
Snozz May. 30 at 8:38 PM
$GH Bad news news for Galleri and broader cancer screening. But could work out for GH if their test stands up to Eu/Uk NHS scrutiny. Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses
1 · Reply
Gator5326
Gator5326 May. 29 at 11:06 AM
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle May. 29 at 10:39 AM
$GH Confident 150 swiftly
2 · Reply
semiguy
semiguy May. 29 at 1:00 AM
$GE $GAP $GH $UNH I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026
0 · Reply
WAJeff
WAJeff May. 28 at 8:00 PM
$GH Nice day!
1 · Reply
Gator5326
Gator5326 May. 28 at 7:33 PM
$GH just getting started. 😎
0 · Reply
OffHisGame88
OffHisGame88 May. 28 at 7:05 PM
$GH Flying!
0 · Reply